Design
Review
This is the authors' abstract. We don't add key points for this paper.
Defective interfering particles (DIPs), derived naturally from viral particles, are not able to replicate on their own. Several studies indicate that DIPs exert antiviral effects via multiple mechanisms. DIPs are able to activate immune responses and suppress virus replication cycles, such as competing for viral replication products, impeding the packaging, release and invasion of viruses. Other studies show that DIPs can be used as a vaccine against viral infection. Moreover, DIPs/DI genomes display antitumor effects by inducing tumor cell apoptosis and promoting dendritic cell maturation. With genetic modified techniques, it is possible to improve its safety against both viruses and tumors. In this review, a comprehensive discussion on the effects exerted by DIPs is provided. We further highlight the clinical significance of DIPs and propose that DIPs can open up a new platform for antiviral and antitumor therapies.
Answers are grounded in this paper and cite their sources.
DIPs may support novel antiviral and antitumor strategies; hypothesis-generating and requires clinical trials before practice change.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: